Publications

Filter Publications By:

Binimetinib / Cancer

05/30/2015

American Society of Clinical Oncology Meeting

A phase Ib/II study of MEK162 (binimetinib) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST)

P.Chi, et al.

Binimetinib / Cancer

05/30/2015

American Society of Clinical Oncology Meeting

A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum

B. J. Monk, MD, et al.

Binimetinib / Cancer

05/30/2015

American Society of Clinical Oncology Meeting

A Phase 1b dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer

R. N. Grisham, MD, et al.

Encorafenib / Cancer

04/20/2015

American Association for Cancer Research Annual Meeting

Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target

C. Krepler, et al.

Binimetinib / Cancer

04/19/2015

American Association for Cancer Research Annual Meeting

Evaluation of the nonclinical activity of the MEK inhibitor binimetinib (MEK162) in combination with paclitaxel in PDX models of HGSOC

S. Winski, et al.

Encorafenib / Cancer

04/18/2015

American Association for Cancer Research Annual Meeting

Phase 1 Study of the Selective BRAF V600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab and With or Without the α-specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF-mutant Colorectal Cancer

J. Schellens, M.D., et al.

ARRY-614 / MDS

12/08/2014

American Society of Hematology Annual Meeting

Efficacy of Dual Inhibition of p38 Mitogen Activated Protein Kinase (MAPK) and Tie-2 Kinase in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

L.S. Bachegowda MD MRCP, et al.

ARRY-614 / MDS

12/05/2014

Clinical Cancer Research

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

G. Garcia-Manero, et al.

Encorafenib / Cancer

11/18/2014

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Phase 1 Study of the Selective BRAF V600 Inhibitor Encorafenib (LGX818) Combined With Cetuximab and With or Without the α-specific PI3K Inhibitor Alpelisib (BYL719) in Patients With Advanced BRAF-mutant Colorectal Cancer

J. Tabernero, et al.

Binimetinib / Cancer

09/29/2014

ESMO

Overall Survival and Biomarker Results From a Phase 2 Study of MEK1/2 Inhibitor Binimetinib (MEK162) in Patients With Advanced NRAS-Mutant Melanoma

C. M. L. van Herpen, et al.